With a market capitalization (market cap) of $1.02B — a measure of how much the company is worth — Pacira BioSciences, Inc. is the 2577th most valuable company in Healthcare as of August 27, 2026. Shares trade at $25.90, up +1.45% on the day.
of 2,591
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves. Pacira also develops its unique multivesicular liposome (MVL) drug delivery technology, which encapsulates therapeutic compounds while preserving their inherent molecular structure. Established in 2006, the firm was formerly known as Pacira Pharmaceuticals, Inc. until its name change to Pacira BioSciences, Inc. in April 2019. Its main corporate office is situated in Tampa, Florida.
Visit websiteAs of August 27, 2026, Pacira BioSciences, Inc. (PCRX) is worth $1.02B — this is its market capitalization, the total value of all its outstanding shares.
Pacira BioSciences, Inc.’s market cap is $1.02B, which ranks it #2577 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Pacira BioSciences, Inc. (PCRX) shares trade at $25.90, up 1.45% on the day, as of August 27, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025
Pacira BioSciences, Inc. trades at a price-to-earnings (P/E) ratio of 161.9, based on its latest share price and annual earnings per share.